tbuckley/cabot-search huggingface dataset:
Failure of Chloroquine prophylaxis in Plasmodium falciparum from East Africa
Authors: A. L. Gardner
Journal: JAMA (1981)

IN 1979, four cases of chloroquineresistant<i>Plasmodium falciparum</i>infections were reported from Kenya and Tanzania.<sup>1-4</sup>All four cases were characterized by RI type of resistance<sup>5</sup>(RI in vivo resistance indicates that, following a 1.5-g [base] dose of chloroquine, the parasitemia clears within seven days but recrudesces from persisting blood forms within 28 days of initiation of therapy). These cases represent the only documented evidence of chloroquine-resistant falciparum malaria in East Africa. We report evidence of another manifestation of chloroquine resistance in East Africa, the development of falciparum malaria in two persons despite adequate chloroquine prophylaxis. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 27-year-old white American woman traveled in rural northeast Tanzania from June 15 to July 6, 1980. One week before her departure, she began and reportedly took 500 mg of chloroquine phosphate (300-mg base) weekly. She continued to follow this same regimen after her return to the United
Evidence-based guidelines for cardiovascular disease prevention in women
Authors: Lori Mosca, Lawrence J Appel, Emelia J Benjamin, Kathy Berra, Nisha Chandra-Strobos, Rosalind P Fabunmi, Deborah Grady, Constance K Haan, Sharonne N Hayes, Debra R Judelson, Nora L Keenan, Patrick McBride, Suzanne Oparil, Pamela Ouyang, Mehmet C Oz, Michael E Mendelsohn, Richard C Pasternak, Vivian W Pinn, Rose Marie Robertson, Karin Schenck-Gustafsson, Cathy A Sila, Sidney C Smith, George Sopko, Anne L Taylor, Brian W Walsh, Nanette K Wenger, Christine L Williams
Journal: Journal of the American College of Cardiology (2004)
WILLIAM BEAUMONT AND ALEXIS ST. MARTIN
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reference Directories
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ATHEROSCLEROSIS, A PROGRESSIVE DISEASE
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PROPHYLAXIS AND TREATMENT OF RHEUMATIC ENDOCARDITIS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INTERNATIONAL EXCHANGE OF PROFESSORS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 247: Heparanase-overexpressed Mesenchymal Stem Cells Enhances Angiogenesis Via Hypoxia-inducible Factor-2α/Vascular Endothelial Growth Factor Receptor-2 Pathway
Authors: Xin Yang Hu, Ling Zhang, Jing Jin, Huiqiang Cheng, Han Chen, Jian-an Wang
Journal: Circulation Research (2014)

Background: Heparanase is an endoglycosidase involved in the cleavage of the heparin sulfate and plays important role in tumor metastasis and angiogenesis. Here we showed heparanase - overexpressed mesenchymal stem cells (MSCs) promoted angiogenesis in rat model after femoral artery ligation, and its underlying mechanism was via endothelial cells migration by Hypoxia-Inducible Factor-2α (HIF-2α) / vascular endothelial growth factor receptor-2 (Flk-1) pathway and collateral formation. Methods: MSCs were transduced with heparanase (MSC heparanase ), control cells were either nontransduced (MSC WT ) or transduced with empty vector (MSC Null ). The effect of human umbilical vein endothelial cells (HUVECs) migration, tube formation and the role for heparanase were determined by transwell, matrigel and arterial rings asaay after co-culture with MSC heparanase , MSC Null and MSC WT conditioned medium. Moreover, right femoral artery was occluded in rats receiving PBS or MSC Null or MSC heparanase , blood flow recovery was assessed by laser-Doppler imaging (LDI) before surgery, immediately after operation, as well as 3, 7 and 14 days after occlusion, capillary density was measured at 14 days after occlusion. Results: In vivo , the group receiving MSC heparanase had a fast recovery of blood flow at 7 days after occlusion and more capillary densities at 14 days after occlusion. In vitro, HUVECs treated with MSC heparanase conditioned medium exhibited increased formation of capillary-like structures and promoted migration, compared with HUVECs treated with MSC Null conditioned medium. All effects of MSC heparanase conditioned medium were abolished by knockdown of HIF-2α and flk-1 with a selective shRNA and were absent in HUVECs. Mechanism studies revealed that heparanase increased the cellular accumulation of HIF-2α protein and affects its nuclear translocation, which regulates flk-1 and its downstream proteins: p38 and HSP27 expression. Conclusions: These findings identify heparanse as a key regulator in MSCs induced angiogenesis and collateral formation. Heparanse up-regulates HIF-2α and mediates Flk-1/p38/HSP27 pathway, which is necessary for angiogenesis and collateral artery network.
New U of I eye center becomes Lions' pride
Authors: M. F. Goldsmith
Journal: JAMA (1985)

One hundred Japanese physicians and hospitals are just about to take part in the first extensive international field test of AMA/NET data bases. James H. Sammons, MD, executive vice-president of the American Medical Association, recently signed an agreement in Chicago to implement the exploratory usage with Yoshio Taniguchi, managing director of Mitsubishi Corporation, Japan's largest trading company. The Tokyo-based conglomerate, through its subsidiary AMS Corporation, will evaluate the market potential in Japan of this computerized telecommunication service of the AMA and GTE Telenet Medical Information Network. The projected year-long link-up is designed to discover whether Japanese physicians, most of whom have, according to an AMA official, "a textbook knowledge" of English, can use the language well enough to benefit from AMA/NET's six medical information data bases. The data bases provide the latest intelligence on Drug Evaluations, Drug Therapy, Disease Information, Socio/Economic Bibliographic Information, EMPIRES Clinical Literature Information, and Medical
Prison rights: mandatory drugs tests and performance indicators for prisons
Authors: S. M Gore, A G. Bird, A. J Ross
Journal: BMJ (1996)

Mandatory drugs testing of prisoners applies throughout England and Wales.Data from the 1995 pilot study in eight prisons show that the proportion testing positive for opiates or benzodiazepines rose from 4.1% to 7.4% between the first and second phase ofrandom testing and that there was a 20% increase over 1993-4 in the provisional total of assaults for 1995.Interpretation of these data is difficult, but this is no excuse for prevarication over the danger that this policy may induce inmates to switch from cannabis (which has a negligible public health risk) to injectable class A drugs (a serious public health risk) in prison.The performance indicators for misuse of drugs that are based on the random mandatory drugs testing programme lack relevant covariate information about the individuals tested and are not reliable or timely for individual prisons.
THE EXPLOSION OF CURRENT BELIEFS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHLORAMPHENICOL
Authors: Wallace C. Ellerbroek
Journal: JAMA (1960)

<h3>To the Editor:—</h3> The report of the Council on Drugs inThe Journal, April 30, 1960, reviewing the occurrence of blood dyscrasias associated with the administration of chloramphenicol (Chloromycetin), was interesting; in seven years, 91 cases of pancytopenia occurred in patients to whom the drug had been given. I am certain that we are all aware, thanks to the publicity provided by the manufacturer, of the potentiality of such a reaction. This drug, which continues to be one of the most useful of the antibiotics is not, according to the Council on Drugs, to be used prophylactically, in trivial infections, or in infections in which other, less dangerous (kanamycin? ristocetin?) antibiotics may be used effectively. It would seem that a follow-up report is due to the medical profession (and to Parke-Davis) from the Council on Drugs; to wit, in exactly how many cases of pancytopenia had this medication been given
Athletic shoe dermatitis. Contact allergy to ethyl butyl thiourea
Authors: J. L. Roberts
Journal: JAMA (1979)

Ten patients with severe foot dermatitis were found to be highly allergic to innersole material prepared by Spenco Medical Corporation and used in Nike athletic shoes. Contact allergy testing showed sensitivity to ethyl butyl thiourea, a chemical accelerator in some neoprene (polychloroprene) rubber products. The dermatitis was recalcitrant and in many cases persisted long after discontinuance of wearing Nike shoes, raising the concern that traces of ethyl butyl thiourea or cross-reacting chemicals may be present in other footwear. (<i>JAMA</i>241:275-276, 1979)
Ethical Guidelines for Organ Transplantation
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enchondroma
Authors: NATASCHA DÖBERT, CHRISTIAN MENZEL, RALF LUDWIG, UWE BERNER, MICHAELA DIEHL, NADJA HAMSCHO, FRANK GRÜNWALD
Journal: Clinical Nuclear Medicine (2002)

A woman was referred for fluorodeoxyglucose positron emission tomography for the staging of a malignant melanoma. Although no signs of metastatic melanoma were evident on the whole-body scan, focally increased uptake within the femoral metaphysis was noted. Radiographic and magnetic resonance examinations revealed an enchondroma as the cause of the increased uptake. Histopathologic verification was obtained. The final diagnosis was actively proliferating enchondroma. A grade I chondrosarcoma could be ruled out. Enchondromas may be responsible for focally increased FDG uptake in bone lesions and must be considered when positron emission tomographic scans obtained with FDG are evaluated in cancer staging.
After Pneumonectomy, What About Other Lung?
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Actinotherapy for General Practitioners.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4625: Mouse strains for cancer research at The Jackson Laboratory Repository
Authors: Deborah Boswell, Stephen Rockwood, Cathleen Lutz
Journal: Cancer Research (2019)

Abstract Genetically defined mice have been the cornerstone of cancer research and resources at The Jackson Laboratory since the founding of the laboratory nearly nine decades ago. The Jackson Laboratory distributes more than 10,500 strains to the scientific community, many with applications in cancer research, including mouse models for specific cancers, xenograft models, immunodeficient platforms for PDX studies, multi-purpose “tool strains” (such as CRISPR cas9-expressing lines), recombinase expressing strains, as well as conditional and inducible expression lines (such as Cre-lox). New to the JAX Repository collection is a KrasLSL-A146T strain with inducible mutant Kras A146T for use in research of gastrointestinal tract and hematological cancers. The tamoxifen-inducible model for pancreatic ductal adenocarcinoma (PDAC), KPCX, and the related conditional activatable Kras allele/floxed Trp53 double mutant line, KP, have recently been developed. Inducible expression of mutant human speckle-type POZ protein (SPOP) in one newly acquired line allows study of prostate tumorigenesis. The portfolio of strains useful for engraftment studies has expanded, complementing the versatile humanized NOD scid gamma (NSG) platform lines. For custom generation of mutant strains, the Repository distributes a variety of research tool strains such as cas9-expressing lines, both constitutive expressing and Cre-inducible models, on different defined genetic backgrounds. Other recently added mutants allow research of the role of inflammation in cancer and screening immunomodulatory cancer therapies. In addition to safeguarding each strain by cryopreservation, the Repository‘s comprehensive quality control program confirms mutation identity and genetic background, and screens for unwanted alleles (such as stray GFP, cre, lacZ, etc.). Investigators can search for specific strains on the JAX Mice website, or peruse the Oncology Therapeutic Area webpage for cancer research related strains and resources. Researchers can submit their strains to be considered for inclusion in the Repository on The Jackson Laboratory website: www.jax.org/donate-a-mouse The Jackson Laboratory Repository is supported by the NIH, The Howard Hughes Medical Institute, and other private charitable foundations. Citation Format: Deborah Boswell, Stephen Rockwood, Cathleen Lutz, The JAX Repository Team. Mouse strains for cancer research at The Jackson Laboratory Repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4625.